These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 8031060)

  • 1. Multiple-drug-resistant mutants of feline immunodeficiency virus selected with 2',3'-dideoxyinosine alone and in combination with 3'-azido-3'-deoxythymidine.
    Gobert JM; Remington KM; Zhu YQ; North TW
    Antimicrob Agents Chemother; 1994 Apr; 38(4):861-4. PubMed ID: 8031060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mutation frequency of feline immunodeficiency virus enhanced by 3'-azido-3'-deoxythymidine.
    LaCasse RA; Remington KM; North TW
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 May; 12(1):26-32. PubMed ID: 8624757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidine.
    Remington KM; Chesebro B; Wehrly K; Pedersen NC; North TW
    J Virol; 1991 Jan; 65(1):308-12. PubMed ID: 1845891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2',3'-dideoxycytidine.
    Medlin HK; Zhu YQ; Remington KM; Phillips TR; North TW
    Antimicrob Agents Chemother; 1996 Apr; 40(4):953-7. PubMed ID: 8849258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine.
    Palmer S; Harmenberg J; Cox S
    Antimicrob Agents Chemother; 1996 May; 40(5):1285-8. PubMed ID: 8723486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study.
    Shirasaka T; Yarchoan R; O'Brien MC; Husson RN; Anderson BD; Kojima E; Shimada T; Broder S; Mitsuya H
    Proc Natl Acad Sci U S A; 1993 Jan; 90(2):562-6. PubMed ID: 8380641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid phenotypic reversion of zidovudine-resistant feline immunodeficiency virus without loss of drug-resistant reverse transcriptase.
    Remington KM; Zhu YQ; Phillips TR; North TW
    J Virol; 1994 Feb; 68(2):632-7. PubMed ID: 7507182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine.
    Gu Z; Gao Q; Li X; Parniak MA; Wainberg MA
    J Virol; 1992 Dec; 66(12):7128-35. PubMed ID: 1279198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.
    Larder BA; Kohli A; Bloor S; Kemp SD; Harrigan PR; Schooley RT; Lange JM; Pennington KN; St Clair MH
    J Virol; 1996 Sep; 70(9):5922-9. PubMed ID: 8709213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential antiviral activities and intracellular metabolism of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine in human cells.
    Mukherji E; Au JL; Mathes LE
    Antimicrob Agents Chemother; 1994 Jul; 38(7):1573-9. PubMed ID: 7526781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of multiple drug resistance by sequential in vitro passage of the human immunodeficiency virus type 1.
    Gao Q; Gu Z; Salomon H; Nagai K; Parniak MA; Wainberg MA
    Arch Virol; 1994; 136(1-2):111-22. PubMed ID: 8002779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidine.
    Smith RA; Remington KM; Preston BD; Schinazi RF; North TW
    J Virol; 1998 Mar; 72(3):2335-40. PubMed ID: 9499094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
    Tisdale M; Kemp SD; Parry NR; Larder BA
    Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutants of feline immunodeficiency virus resistant to 2',3'-dideoxy-2',3'-didehydrothymidine.
    Zhu YQ; Remington KM; North TW
    Antimicrob Agents Chemother; 1996 Sep; 40(9):1983-7. PubMed ID: 8878567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.
    St Clair MH; Martin JL; Tudor-Williams G; Bach MC; Vavro CL; King DM; Kellam P; Kemp SD; Larder BA
    Science; 1991 Sep; 253(5027):1557-9. PubMed ID: 1716788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human immunodeficiency virus inhibition is prolonged by 3'-azido-3'-deoxythymidine alternating with 2',3'-dideoxycytidine compared with 3'-azido-3'-deoxythymidine alone.
    Spector SA; Ripley D; Hsia K
    Antimicrob Agents Chemother; 1989 Jun; 33(6):920-3. PubMed ID: 2548440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro.
    Mathez D; Schinazi RF; Liotta DC; Leibowitch J
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2206-11. PubMed ID: 7504908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.
    Gao Q; Gu Z; Hiscott J; Dionne G; Wainberg MA
    Antimicrob Agents Chemother; 1993 Jan; 37(1):130-3. PubMed ID: 8381634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine.
    Gao Q; Gu ZX; Parniak MA; Li XG; Wainberg MA
    J Virol; 1992 Jan; 66(1):12-9. PubMed ID: 1727474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro.
    Johnson VA; Merrill DP; Videler JA; Chou TC; Byington RE; Eron JJ; D'Aquila RT; Hirsch MS
    J Infect Dis; 1991 Oct; 164(4):646-55. PubMed ID: 1716649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.